A glucagon and GLP-1 receptor dual agonist showed promise for reducing liver fat in a phase II study of patients with metabolic dysfunction-associated steatotic liver disease and steatohepatitis. ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results